We collected information about Myokardia Inc Hours for you. Follow the liks to find out everything about Myokardia Inc Hours.
https://www.crunchbase.com/organization/myokardia
MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in.
https://www.annualreports.com/Company/myokardia-inc
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ...
https://pitchbook.com/profiles/company/55285-12
MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure ...
https://craft.co/myokardia
BRISBANE, Calif. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program , who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of.
https://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash
Telephone replay will be available approximately three hours after the call until 11:30 a.m. ET on October 19, 2020. ... Corporate Communications and Investor Relations MyoKardia, Inc. 650-351 ...
https://www.fool.com/investing/2020/10/07/heres-why-bristol-myers-offered-myokardia-131-bill/
Here's Why Bristol Myers Offered MyoKardia $13.1 Billion By Cory Renauer - Oct 7, 2020 at 7:43AM You’re reading a free article with opinions that …
https://finance.yahoo.com/news/myokardia-inc-nasdaq-myok-insiders-185826123.html
MyoKardia Insiders Are Selling The Stock. We have seen a bit of insider selling at MyoKardia, over the last three months. The selling netted US$122k for Anastasios Gianakakos. But (as above)at ...
https://www.marketscreener.com/quote/stock/MYOKARDIA-INC-24749772/news/
MYOKARDIA, INC. : News, information and stories for MYOKARDIA, INC. | Nasdaq: MYOK | Nasdaq
https://www.marketwatch.com/story/bristol-myers-fda-extends-review-of-heart-drug-mavacamten-by-three-months-271637324403?mod=newsviewer_click
Mavacamten was the lead product candidate of MyoKardia Inc., which Bristol-Myers bought last year for about $13.1 billion. Write to …
https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx
MyoKardia . Michelle Corral Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 [email protected]. Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 [email protected]. Julie Normart (media) W2O 628-213-3754 [email protected]. Source: Bristol Myers Squibb
Searching for Myokardia Inc Hours?
You can just click the links above. The info is collected for you.
